Loading... Please wait... Loading... Please wait...
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
ClearPoint Neuro, Inc. operates as a medical device company primarily in the United States. The company develops and commercializes platforms for performing minimally invasive surgical procedures in the brain under direct, and intra-procedural magnetic resonance imaging (MRI) guidance. It offers ClearPoint system for the insertion of deep brain stimulation electrodes and biopsy needles, and the infusion of pharmaceuticals and laser catheters into the brain; and ClearPoint Neuro Navigation System, an MRI suite. It has license and collaboration agreements with Boston Scientific Corporation, The Johns Hopkins University, Clinical Laserthermia Systems Americas Inc, Koninklijke Philips N.V., Blackrock Neurotech, and University of California and San Francisco. The company was formerly known as MRI Interventions, Inc. and changed its name to ClearPoint Neuro, Inc. in February 2020. ClearPoint Neuro, Inc. was incorporated in 1998 and is headquartered in Solana Beach, California.
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
ClearPoint Neuro's business continues to perform well despite the stock struggling. The drug delivery business is thriving, which should be aided by maturing partner programs and the introduction of n...
SOLANA BEACH, Calif., June 20, 2024 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global device, cell, and gene therapy-enabling company offering precise navigation ...
Aspen Neuroscience Announces MRI-Guided Transplantation Approach for ASPIRO Clinical Trial with the ClearPoint® Navigation System SAN DIEGO , June 20, 2024 /PRNewswire/ -- Aspen Neuroscience, Inc. a...
ClearPoint (CLPT) announces the full market release of the SmartFrame OR platform, intended for performing DBS, and Prism Neuro Laser Therapy System for providing thermal therapy....
SOLANA BEACH, Calif., June 01, 2024 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global device, cell, and gene therapy-enabling company offering precise navigation ...
The consensus price target hints at an 81.5% upside potential for ClearPoint Neuro (CLPT). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings...
The mean of analysts' price targets for ClearPoint Neuro (CLPT) points to a 70.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among...
ClearPoint Neuro, Inc. (NASDAQ:CLPT ) Q1 2024 Earnings Conference Call May 7, 2024 4:30 PM ET Company Participants Joe Burnett – Chief Executive Officer Danilo D'Alessandro – Chief Financial Offic...
NEW YORK , May 2, 2024 /PRNewswire/ -- Purcell & Lefkowitz LLP announces that it is investigating ClearPoint Neuro, Inc. (NASDAQ: CLPT) on behalf of the company's shareholders. The investigation see...
